Last CNY19.44 CNY
Change Today -0.30 / -1.52%
Volume 3.7M
As of 2:00 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

zhejiang jingxin pharmaceu-a (002020) Snapshot

Open
CNY19.70
Previous Close
CNY19.74
Day High
CNY19.99
Day Low
CNY19.39
52 Week High
10/9/14 - CNY22.15
52 Week Low
03/28/14 - CNY14.25
Market Cap
5.6B
Average Volume 10 Days
2.6M
EPS TTM
CNY0.39
Shares Outstanding
286.5M
EX-Date
05/23/14
P/E TM
50.1x
Dividend
CNY0.10
Dividend Yield
0.51%
Current Stock Chart for ZHEJIANG JINGXIN PHARMACEU-A (002020)

Related News

No related news articles were found.

zhejiang jingxin pharmaceu-a (002020) Related Businessweek News

No Related Businessweek News Found

zhejiang jingxin pharmaceu-a (002020) Details

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells finished dosage forms, APIs, and Chinese herbal drugs in China. It focuses on novelty and generic drugs for anti-infective, cardiovascular, and cerebrovascular diseases, including hypertension, hyperlipemia, hyperglycemia, and antiplatelet coagulating; and central nervous system drugs, such as antidepressant, antipsychotic, antiparkinsonian, anti-alzheimer's disease, sedative-hypnotic, and anticonvulsant. The company’s finished dosage forms include tablets, capsules, injections, and powders for injections in the areas of antilipemic, antidiabetic, antihypertensive, antidepressant, gastrointestinal promotion, antihistamine, cerebrovarscular, quitting smoking assistant, anti-inflammatory analgesic, and antibiotics. Zhejiang Jingxin Pharmaceutical Co., Ltd. exports its products to South-East Asia, South Asia, Latin America, and Europe. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974 and is headquartered in Xinchang, China.

Founded in 1974

zhejiang jingxin pharmaceu-a (002020) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zhejiang jingxin pharmaceu-a (002020) Key Developments

Zhejiang Jingxin Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Dec 05, 2014

Zhejiang Jingxin Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Dec 05, 2014., at 14:00 China Standard Time. Agenda: To consider use of proprietary fund to purchase bank principal-guaranteed wealth management products.

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report Q3, 2014 Results on Oct 28, 2014

Zhejiang Jingxin Pharmaceutical Co., Ltd. announced that they will report Q3, 2014 results on Oct 28, 2014

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report First Half, 2014 Results on Aug 26, 2014

Zhejiang Jingxin Pharmaceutical Co., Ltd. announced that they will report first half, 2014 results on Aug 26, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002020:CH CNY19.44 CNY -0.30

002020 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002020.
View Industry Companies
 

Industry Analysis

002020

Industry Average

Valuation 002020 Industry Range
Price/Earnings 49.3x
Price/Sales 4.7x
Price/Book 4.0x
Price/Cash Flow 54.1x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZHEJIANG JINGXIN PHARMACEU-A, please visit www.jingxinpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.